Nabumetone

萘丁美酮

Report date: 2023/02/20 13:30:35
NME

Base Information

Drug NameNabumetone
Drug Alias NameNabumetonas萘丁酮奈丁美酮Nabumetoni续丁美续 +[15] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclooxygenases inhibitors
TargetsCyclooxygenases
Therapy Area/IndicationsSoft Tissue InjuriesPainRheumatic Diseases +[6] 
Global Approved IndicationsSoft Tissue InjuriesPainRheumatic Diseases +[6] 
Approved Indications in ChinaSoft Tissue InjuriesPainRheumatic Diseases +[4] 
Original Approved Country/TerritoryN/A
Original Approved Date1984/01/01
Country/TerritoryUnited StatesIndiaMainland China +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcSanwa Kagaku Kenkyusho Co Ltd Kumamoto FactorySichuan Pudu Pharmaceutical Factory
Inactive CompaniesActavis IncSmithkline Beecham (Cork) LtdDr.Reddy's Laboratories Ltd
Active IndicationsSoft Tissue InjuriesPainRheumatic Diseases +[4] 
Inactive IndicationsOsteoarthritisArthritis, Rheumatoid

Other Information

ATC CodeM01AX01
Related LinksWikipediaDrugBankKEGG